Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in early-stage HER2 positive breast cancer.

Scientific reports - 13 Jul 2021

Vazdar Ljubica, Gabrić Ivo Darko, Kruljac Ivan, Pintarić Hrvoje, Šeparović Robert, Kirigin Biloš Lora Stanka, Pavlović Mirjana, Tečić Vuger Ana, Štefanović Mario

Abstract excerpt

Trastuzumab has improved the prognosis of HER2 positive breast cancer, but cardiotoxicity remains a concern. We aimed to identify risk factors for trastuzumab-induced cardiotoxicity, with an emphasis on the HER2 Ile655Val single nucleotide polymorphism. This single-center case-control study included 1056 patients with early-stage HER2 positive breast cancer that received adjuvant trastuzumab. Cardiotoxicity was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cardiotoxicity

Share to Case-Control Studies

Share to Neoplasm Staging

Share to Receptor, ErbB-2

Share to Risk Factors

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 34257352
DOI: 10.1038/s41598-021-93634-6
PMCID: PMC8277791

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in early-stage HER2 positive breast cancer.PMID 34257352Read ↗

Influence of the HER2 Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients: a meta-analysis.Semantic proximity Read ↗

HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients.Semantic proximity Read ↗

Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity.Semantic proximity Read ↗

Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trialSemantic proximity Read ↗

Mechanisms and Genetic Susceptibility of Chemotherapy-Induced Cardiotoxicity in Patients With Breast Cancer.Semantic proximity Read ↗

Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study.Semantic proximity Read ↗

Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab.Semantic proximity Read ↗

The incidence of adjuvant chemotherapy-related early-onset cardiac events in breast cancer patients and its relationship with genetic susceptibility: A prospective cohort studySemantic proximity Read ↗

A Genome-Wide Association Study Identifies Five Novel Genetic Markers for Trastuzumab-Induced Cardiotoxicity in Japanese PopulationSemantic proximity Read ↗

Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial.Semantic proximity Read ↗

Trastuzumab-induced cardiotoxicity: is it a personalized risk?Semantic proximity Read ↗

Genome-wide association study of genetic variants related to anthracycline-induced cardiotoxicity in early breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.